Human monoclonal antibodies to FC alpha receptor (CD89)
US7192582B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2002 |
| Grant date | Mar 20, 2007 |
| Priority date | — |
| Expiry date | Sep 29, 2022 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human monoclonal antibodies which bind specifically to Fc alpha receptor (CD89), including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.